CDTX
Cidara Therapeutics, Inc.
Biotechnology
Market Cap$6.96B
5Y Perf.+205.8%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
CDTX vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1669.52T
5Y Perf.-60.5%
CDTX vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | CDTX | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $6.96B | $1669.52T |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-185M | $-168M |
| Gross Margin | 100.0% | — |
| Operating Margin | -138.1% | — |
| Total Debt | $4M | $22M |
| Cash & Equiv. | $190M | $194M |
CDTX vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CDTX
DBVT
| Stock | May 20 | Jan 26 | Return |
|---|---|---|---|
| Cidara Therapeutics… (CDTX) | 100 | 305.8 | +205.8% |
| DBV Technologies S.… (DBVT) | 100 | 39.5 | -60.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CDTX vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: CDTX leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
CDTX
Cidara Therapeutics, Inc.
The Income Pick
CDTX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- beta 0.87
- Rev growth -94.5%, EPS growth -409.5%, 3Y rev CAGR -70.5%
- -16.9% 10Y total return vs DBVT's -87.1%
Best for: income & stability and growth exposure
DBVT
DBV Technologies S.A.
The Quality Compounder
DBVT is the clearest fit if your priority is quality.
- 0.3% margin vs CDTX's -133.2%
Best for: quality
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | CDTX | -94.5% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs CDTX's -133.2% |
| Stability / Safety | CDTX | Beta 0.87 vs DBVT's 1.26, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | CDTX | +9.3% vs DBVT's +110.7% |
| Efficiency (ROA) | CDTX | -35.6% ROA vs DBVT's -89.0% |
CDTX vs DBVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
Segment breakdown not available.
CDTX vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLCDTXLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
CDTXCidara Therapeutics, …
3leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
CDTX5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
CDTX5/6
Risk & VolatilityBeta, volatility, and downside exposure
CDTX2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
CDTX and DBVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | CDTXCidara Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$195M | -$112M |
| Net IncomeAfter-tax profit | -$185M | -$168M |
| Free Cash FlowCash after capex | -$133M | -$151M |
| Gross MarginGross profit ÷ Revenue | +100.0% | — |
| Operating MarginEBIT ÷ Revenue | -138.1% | — |
| Net MarginNet income ÷ Revenue | -133.2% | — |
| FCF MarginFCF ÷ Revenue | -138.6% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | -30.3% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — CDTX and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | CDTXCidara Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $7.0B | $1669.52T |
| Enterprise ValueMkt cap + debt − cash | $6.8B | $1669.52T |
| Trailing P/EPrice ÷ TTM EPS | -8.28x | -0.74x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 5460.07x | — |
| Price / BookPrice ÷ Book value/share | 8.61x | 0.64x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — CDTX and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
CDTX leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
CDTX delivers a -43.7% return on equity — every $100 of shareholder capital generates $-44 in annual profit, vs $-130 for DBVT. CDTX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x. On the Piotroski fundamental quality scale (0–9), DBVT scores 4/9 vs CDTX's 3/9, reflecting mixed financial health.
| Metric | CDTXCidara Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -43.7% | -130.2% |
| ROA (TTM)Return on assets | -35.6% | -89.0% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -2.1% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 4 |
| Debt / EquityFinancial leverage | 0.02x | 0.13x |
| Net DebtTotal debt minus cash | -$186M | -$172M |
| Cash & Equiv.Liquid assets | $190M | $194M |
| Total DebtShort + long-term debt | $4M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
CDTX leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
CDTX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CDTX five years ago would be worth $54,797 today (with dividends reinvested), compared to $3,041 for DBVT. Over the past 12 months, CDTX leads with a +929.7% total return vs DBVT's +110.7%. The 3-year compound annual growth rate (CAGR) favors CDTX at 119.3% vs DBVT's 5.7% — a key indicator of consistent wealth creation.
| Metric | CDTXCidara Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +0.2% | +2.3% |
| 1-Year ReturnPast 12 months | +929.7% | +110.7% |
| 3-Year ReturnCumulative with dividends | +954.2% | +18.1% |
| 5-Year ReturnCumulative with dividends | +448.0% | -69.6% |
| 10-Year ReturnCumulative with dividends | -16.9% | -87.1% |
| CAGR (3Y)Annualised 3-year return | +119.3% | +5.7% |
CDTX leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
CDTX leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CDTX is the less volatile stock with a 0.87 beta — it tends to amplify market swings less than DBVT's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CDTX currently trades 100.0% from its 52-week high vs DBVT's 74.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CDTXCidara Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.87x | 1.26x |
| 52-Week HighHighest price in past year | $221.42 | $26.18 |
| 52-Week LowLowest price in past year | $18.51 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +100.0% | +74.4% |
| RSI (14)Momentum oscillator 0–100 | 84.8 | 43.7 |
| Avg Volume (50D)Average daily shares traded | 0 | 249K |
CDTX leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CDTX as "Buy" and DBVT as "Buy". Consensus price targets imply 137.7% upside for DBVT (target: $46) vs 0.1% for CDTX (target: $222).
| Metric | CDTXCidara Therapeuti… | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $221.50 | $46.33 |
| # AnalystsCovering analysts | 11 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CDTX leads in 3 of 6 categories (Profitability & Efficiency, Total Returns). DBVT leads in 1 (Income & Cash Flow). 1 tied.
Best OverallCidara Therapeutics, Inc. (CDTX)Leads 3 of 6 categories
Loading custom metrics...
CDTX vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CDTX or DBVT a better buy right now?
Analysts rate Cidara Therapeutics, Inc.
(CDTX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CDTX or DBVT?
Over the past 5 years, Cidara Therapeutics, Inc.
(CDTX) delivered a total return of +448. 0%, compared to -69. 6% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: CDTX returned -16. 9% versus DBVT's -87. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CDTX or DBVT?
By beta (market sensitivity over 5 years), Cidara Therapeutics, Inc.
(CDTX) is the lower-risk stock at 0. 87β versus DBV Technologies S. A. 's 1. 26β — meaning DBVT is approximately 45% more volatile than CDTX relative to the S&P 500. On balance sheet safety, Cidara Therapeutics, Inc. (CDTX) carries a lower debt/equity ratio of 2% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — CDTX or DBVT?
On earnings-per-share growth, the picture is similar: DBV Technologies S.
A. grew EPS -347. 5% year-over-year, compared to -409. 5% for Cidara Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CDTX or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -133. 2% for Cidara Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -138. 1% for CDTX. At the gross margin level — before operating expenses — CDTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CDTX or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CDTX or DBVT better for a retirement portfolio?
For long-horizon retirement investors, Cidara Therapeutics, Inc.
(CDTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Both have compounded well over 10 years (CDTX: -16. 9%, DBVT: -87. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CDTX and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.